register

News & Trends - Pharmaceuticals

MSD’s spinoff Organon to acquire medical device company for $240M

Health Industry Hub | April 7, 2021 |

Pharma News: MSD (known as Merck in United States and Canada) has entered a definitive agreement in which its intended spinoff Organon will acquire the commercial-stage medical device company Alydia Health for a total of up to $240 million.

Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum haemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.

The transaction is expected to close after Organon has spun off from MSD as a standalone publicly traded company late in the second quarter of this year.

“The acquisition aligns with Organon’s strategy to become a global leader in women’s health by focusing our product development on her unmet medical needs,” said Kevin Ali, CEO of Organon.

Digital & Innovation - Health Industry Hub Digital Series

“We believe that Organon’s strong global commercial footprint in reproductive health, in conjunction with Alydia’s rapidly growing commercial capabilities, will help enable growth of the Jada System, including potential expansion into Europe and other developed countries, as well as in the world’s least developed markets where Organon has significant experience creating affordable access,” he added.

“Alydia Health is thrilled to join Organon as we hold a similar vision to bring technology and therapeutic solutions to market that can improve outcomes for women in need across the globe,” said Rob Binney, CEO of Alydia Health.

“Our goal is to help make childbirth safer for more women. With critical gaps in maternal care, we believe this acquisition will potentially accelerate the delivery of the Jada System to more women and communities in need,” he said.

The Jada System is intended to provide control and treatment of abnormal postpartum uterine bleeding or haemorrhage when conservative management is warranted. The safety and effectiveness of the Jada System was evaluated in the PEARLE study, a prospective, single-arm, clinical trial, under an approved investigational device exemption from the U.S. Food and Drug Administration (FDA).


News & Trends - MedTech & Diagnostics

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: In the past five years, 71 private hospital services have closed down as a result of […]

More


News & Trends - Pharmaceuticals

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Health Industry Hub | June 20, 2024 |

Pharma News: Over 400 medicines are currently facing shortages nationwide, according to the Therapeutic Goods Administration (TGA). Among these, 39 […]

More


News & Trends - MedTech & Diagnostics

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: As Australia marks Bowel Cancer Awareness Month this June, the HCF Research Foundation highlights its support […]

More


Digital & Innovation

Australian AI-powered tool promises rapid stroke detection

Australian AI-powered tool promises rapid stroke detection

Health Industry Hub | June 20, 2024 |

Digital & Innovation: An Australian innovation promises to transform stroke care by enabling quicker intervention and improving patient outcomes through […]

More


This content is copyright protected. Please subscribe to gain access.